Tuesday Features

Zalicus awaiting data on potential new pain medication

Zalicus (NASADQ:ZLCS) will have data in the second half of this year that will provide important insights into the potential of its lead drug candidate, Z160, to be a breakthrough new class of non-opioid analgesic for the treatment of both chronic and acute neuropathic pain. Justin Renz “There hasn’t been a lot of innovation in the pain space in... [Read more of this feature]

---

Galena to target Abstral as market leader for cancer pain

Galena Biopharma (NASDAQ:GALE) plans to make its recently acquired Abstral sublingual tablets the market leader for the treatment of breakthrough cancer pain (BTcP) in the U.S., matching the product’s performance in Europe. Mark J. Ahn, PhD “Abstral is the latest and best-in-class drug for this indication,” president and CEO Mark Ahn says in an... [Read more of this feature]

---

Oramed readies oral insulin study in U.S.

Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. Nadav Kidron “Approving a clinical trial in the U.S. for oral insulin is a big deal,”... [Read more of this feature]

---

More Posts From Tuesday Features

Briefs

Ohr Pharma names June Almenoff to board

Dr. June Almenoff Ohr Pharmaceutical (OTCQB: OHRP)has appointed Dr. June Almenoff to the board of directors. In a statement, CEO Dr. Irach Taraporewala said Dr. Almenoff offers tremendous expertise in the areas of pharmaceutical research and development, risk management, and product licensing. “We look forward to working with June as we continue... [Read more of this brief]

---

Aradigm inks development pact with Grifols

Grifols (NASDAQ:GRFS) of Spain and Aradigm (OTCBB:ARDM) have signed an exclusive, worldwide license for Aradigm’s proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase 2b clinical trials in BE patients... [Read more of this brief]

---

Oramed cleared for oral insulin trials in U.S.

The FDA has cleared Oramed Pharmaceuticals’ (NASDAQ:ORMP) Investigational New Drug application for ORMD-0801, its oral insulin capsule. Nadav Kidron “We are very pleased to have the FDA clearance to proceed,” CEO Nadav Kidron said in a statement. “The upcoming trial is a major milestone for Oramed and we look forward to continuing... [Read more of this brief]

---

Medigus to present three-year follow-up data of SRS pivotal study at DDW

Medigus (TASE:MDGS) will be presenting the successful three-year follow-up data of the SRS pivotal study at the Digestive Disease Week in Orlando on May 18 to 21. The study, conducted at Indiana University, clearly indicates that the majority of patients treated by Medigus’ endoscopic system SRS were able to stop taking daily PPl (drugs that have... [Read more of this brief]

---

Stephens starts TearLab at overweight

Stephens Inc. has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with an “overweight” rating and an $11 price target, saying the company is attractively positioned with a unique technology that addresses a large unmet need for the diagnosis and management of dry eye disease.   The stock was quoted at $9.46 Thursday afternoon. “We are very... [Read more of this brief]

---

More Posts From Briefs